GN
GNNSF.US Genscript Biotech Corporation
- Market cap
- USD 8.73B
- P/E
- -
- P/B
- 2.51x
- ROE
- -13.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is GNNSF.US undervalued?
Graham numberThe Graham number of Genscript Biotech Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genscript Biotech Corporation fundamental analysis
No fundamental analysis for Genscript Biotech Corporation yet.
Genscript Biotech Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which ar…
Full company profileGenscript Biotech Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genscript Biotech Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 115M | 153M | 231M | 273M | 391M | 511M | 626M | 840M | 594M | 961M | 1.61B |
| Gross Profit | 76.2M | 105M | 159M | 180M | 256M | 283M | 304M | 410M | 272M | 554M | 825M |
| Operating Income | 32.5M | 37.5M | 22.4M | -112M | -205M | -368M | -436M | -416M | 9.28M | 256M | 198M |
| EBITDA | 37.9M | 45.5M | 35.7M | -92.6M | -172M | -466M | -354M | -249M | 71.1M | 330M | 359M |
| Net Income | 26.2M | 26.1M | 21.2M | -96.9M | -205M | -359M | -227M | -95.5M | 2.96B | -534M | -516M |
| EPS | 0.02 | 0.02 | 0.01 | -0.05 | -0.11 | -0.18 | -0.11 | -0.05 | 1.36 | -0.25 | -0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 226M | 504M | 917M | 889M | 1.45B | 2.23B | 2.55B | 3.39B | 5.28B | 4.85B | 4.79B |
| Total Liabilities | 42.0M | 276M | 424M | 517M | 632M | 1.14B | 1.18B | 1.34B | 955M | 876M | 881M |
| Shareholders' Equity | 178M | 218M | 479M | 383M | 902M | 1.05B | 1.01B | 1.39B | 4.32B | 3.96B | 3.88B |
| Cash & Short-term Investments | 136M | 127M | 565M | 427M | 771M | 1.40B | 1.46B | 1.93B | 621M | 843M | 831M |
| Total Debt | 48.0K | 1.11M | 10.5M | 24.1M | 55.0M | 156M | 350M | 417M | 171M | 609M | 344M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 33.3M | 21.4M | 295M | -30.0M | -151M | -137M | -120M | -287M | 75.6M | 326M | 226M |
| Capital Expenditure | 8.98M | 32.0M | 79.6M | 119M | 128M | 137M | 204M | 158M | 148M | 83.8M | 204M |
| Free Cash Flow | 24.3M | -10.6M | 216M | -148M | -279M | -274M | -324M | -445M | -72.3M | 242M | -17.0M |
| Ratios | |||||||||||
| ROE | 14.7% | 12.0% | 4.4% | -25.3% | -22.7% | -34.3% | -22.4% | -6.9% | 68.5% | -13.5% | -13.3% |
| ROA | 11.6% | 5.2% | 2.3% | -10.9% | -14.2% | -16.1% | -8.9% | -2.8% | 56.1% | -11.0% | -10.8% |
| Net Profit Margin | 22.8% | 17.1% | 9.2% | -35.5% | -52.4% | -70.2% | -36.3% | -11.4% | 498.2% | -55.5% | -32.0% |
| Debt to Equity | 0.00x | 0.01x | 0.02x | 0.06x | 0.06x | 0.15x | 0.35x | 0.30x | 0.04x | 0.15x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genscript Biotech Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 5, 2017
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 202M | 0.11 | - |
| 2019 | USD 25.8M | 0.01 | - |
| 2018 | - | - | - |
| 2017 | USD 2.64M | 0.00 | 10.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Genscript Biotech Corporation
- Insiders 35.19%
- Institutions 28.96%
- Public & others 35.86%
- Shares outstanding 2.28B
- Free float 1.41B
Genscript Biotech Corporation company profile
- Company name
- Genscript Biotech Corporation
- Ticker
- GNNSF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,135
- Fiscal year end
- December
- Address
- Dah Sing Financial Centre, Wan Chai, Hong Kong
- Phone
- 86 25 5889 7288
- Website
- genscript.com
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Genscript Biotech Corporation management
10- Mr. Jiange MengExecutive Chairman · born 1968
- Ms. Weihui ShaoCEO & COO · born 1980
- Ms. Ye Wang M.S.Co-Founder, President & Executive Director · born 1968
- Dr. Fangliang Zhang EMBA, Ph.D.Co-Founder & Executive Director · born 1965
- Dr. Li Zhu Ph.D.Chief Strategy Officer & Executive Director · born 1950
- Mr. Jing ZhouChief Financial Officer · born 1979
- Dr. Kening Li J.D.General Counsel & Chief Compliance Officer
- Ms. Aylin Kosova BilginChief Marketing & Corporate Communications Officer
- Dr. Bhama ParimooHead of Global Diversity, Equity & Inclusion(DEI)
- Mr. Ernest LeeHead of Sustainability